260 related articles for article (PubMed ID: 26984415)
1. Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.
Haugvik SP; Kaemmerer D; Gaujoux S; Labori KJ; Verbeke CS; Gladhaug IP
Curr Oncol Rep; 2016 May; 18(5):28. PubMed ID: 26984415
[TBL] [Abstract][Full Text] [Related]
2. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic value of FNA biopsy in grading pancreatic neuroendocrine tumors.
Laskiewicz L; Jamshed S; Gong Y; Ainechi S; LaFemina J; Wang X
Cancer Cytopathol; 2018 Mar; 126(3):170-178. PubMed ID: 29266776
[TBL] [Abstract][Full Text] [Related]
4. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
[TBL] [Abstract][Full Text] [Related]
5. Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors.
Philips P; Kooby DA; Maithel S; Merchant NB; Weber SM; Winslow ER; Ahmad S; Kim HJ; Scoggins CR; McMasters KM; Martin RCG
Pancreas; 2018 Mar; 47(3):326-331. PubMed ID: 29351120
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.
Larghi A; Capurso G; Carnuccio A; Ricci R; Alfieri S; Galasso D; Lugli F; Bianchi A; Panzuto F; De Marinis L; Falconi M; Delle Fave G; Doglietto GB; Costamagna G; Rindi G
Gastrointest Endosc; 2012 Sep; 76(3):570-7. PubMed ID: 22898415
[TBL] [Abstract][Full Text] [Related]
7. Can a High-grade Neuroendocrine Carcinoma be Functional?
Graham C; Chauhan A; Anthony L
Am J Med Sci; 2019 Mar; 357(3):258-262. PubMed ID: 30638597
[TBL] [Abstract][Full Text] [Related]
8. High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors.
Zhou B; Xiang J; Jin M; Zheng X; Li G; Yan S
BMC Cancer; 2021 Mar; 21(1):334. PubMed ID: 33789624
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract][Full Text] [Related]
11. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
13. Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry.
Mintziras I; Keck T; Werner J; Fichtner-Feigl S; Wittel U; Senninger N; Vowinkel T; Köninger J; Anthuber M; Geißler B; Bartsch DK;
Surg Today; 2019 Dec; 49(12):1013-1021. PubMed ID: 31240463
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms.
Hamilton NA; Liu TC; Cavatiao A; Mawad K; Chen L; Strasberg SS; Linehan DC; Cao D; Hawkins WG
Surgery; 2012 Jul; 152(1):107-13. PubMed ID: 22503317
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
16. Morphological and immunohistochemical profile of pancreatic neuroendocrine neoplasms.
Simtniece Z; Vanags A; Strumfa I; Sperga M; Vasko E; Prieditis P; Trapencieris P; Gardovskis J
Pol J Pathol; 2015 Jun; 66(2):176-94. PubMed ID: 26247532
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.
Ohmoto A; Rokutan H; Yachida S
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098761
[TBL] [Abstract][Full Text] [Related]
18. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors.
Kim D; Viswanathan K; Goyal A; Rao R
Cancer Cytopathol; 2020 Apr; 128(4):269-277. PubMed ID: 31977134
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
[TBL] [Abstract][Full Text] [Related]
20. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining.
Jamali M; Chetty R
Endocr Pathol; 2008; 19(4):282-8. PubMed ID: 18931958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
